Repligen (NASDAQ:RGEN) Stock Rating Lowered by BidaskClub

Repligen (NASDAQ:RGEN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday, BidAskClub reports.

Other research analysts have also issued reports about the company. Craig Hallum upped their target price on Repligen from $80.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Stephens reiterated an “overweight” rating and set a $110.00 price target on shares of Repligen in a research note on Thursday, August 22nd. First Analysis upped their price target on Repligen from $95.00 to $107.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Repligen in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Repligen has an average rating of “Buy” and a consensus price target of $101.17.

RGEN stock traded up $0.98 during mid-day trading on Wednesday, hitting $79.99. The stock had a trading volume of 10,685 shares, compared to its average volume of 535,378. The company has a current ratio of 2.25, a quick ratio of 1.88 and a debt-to-equity ratio of 0.02. Repligen has a 1-year low of $48.26 and a 1-year high of $99.25. The company has a fifty day moving average of $91.31 and a 200 day moving average of $74.42. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of 109.53, a PEG ratio of 4.73 and a beta of 1.16.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.06. Repligen had a return on equity of 6.92% and a net margin of 11.42%. The company had revenue of $70.70 million for the quarter, compared to analyst estimates of $65.47 million. During the same period in the prior year, the firm posted $0.14 EPS. The business’s revenue was up 48.1% compared to the same quarter last year. As a group, sell-side analysts expect that Repligen will post 0.97 earnings per share for the current fiscal year.

In other news, Director Karen A. Dawes sold 1,295 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $77.35, for a total transaction of $100,168.25. Following the completion of the sale, the director now owns 118,329 shares in the company, valued at approximately $9,152,748.15. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 12,094 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $82.40, for a total value of $996,545.60. Following the sale, the chief executive officer now owns 210,976 shares of the company’s stock, valued at approximately $17,384,422.40. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Royce & Associates LP boosted its stake in Repligen by 40.6% during the 1st quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 145 shares during the period. Advisors Preferred LLC bought a new stake in Repligen during the 2nd quarter valued at approximately $39,000. South Dakota Investment Council bought a new stake in Repligen during the 1st quarter valued at approximately $83,000. C M Bidwell & Associates Ltd. bought a new stake in Repligen during the 2nd quarter valued at approximately $84,000. Finally, Ropes Wealth Advisors LLC bought a new stake in Repligen during the 2nd quarter valued at approximately $116,000. Hedge funds and other institutional investors own 88.66% of the company’s stock.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: What is total return in investing?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.